Blincyto (blinatumomab) - Risk Of Pancreatitis

BLINCYTO Recall Summary BLINCYTO (blinatumomab), a cancer treatment drug, is being recalled across Canada because it may increase the risk of pancreatitis (inflammation of the pancreas). This recall affects all patients in Canada who are using or have been prescribed this medication.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-07-13

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/857ce071-3b85-46df-94d9-8069bf3f5f51